Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27

Overview of attention for article published in Frontiers in oncology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 23,890 followers.

Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27 https://t.co/8JqiUPs8xF https://t.co/XRgF6RC3MF

25 Jan 2023

Reply Repost Favourite

Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27 https://t.co/g1mx6lfuPk https://t.co/7U20VYlyL4

09 Jan 2023

Reply Repost Favourite

New research: Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27: Objective To investigate the effect of Hsp27 and the inhibitory effect of Atractylenolide I (ATL-1) on the… https://t.co

06 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.